You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY21 is not expected to be complete until September, 2022.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Combat Casualty Handoff Automated Trainer (CCHAT)

    SBC: SOAR TECHNOLOGY, INC.            Topic: DHA17B001

    Combat casualty handoffs are critical communication moments during which responsibility for the patient and important casualty information is transferred between providers. The nature of these handoffs requires specialized training, for which no standardized framework currently exists. The proposed effort aims to develop a capability, compatible with current DoD systems, that provides caregivers w ...

    STTR Phase I 2018 Department of DefenseDefense Health Agency
  2. CCHAT Handoff Protocol

    SBC: SOAR TECHNOLOGY, INC.            Topic: DHA17B002

    Research has identified that handoffs are particularly important communication processes, during which communication error can lead to patient safety situations. Organizations have created standard practices and training materials to encourage teamwork communication for handoffs, however these do not necessarily capture the needs of military medicine of combat casualty care. Combat casualty handof ...

    STTR Phase I 2018 Department of DefenseDefense Health Agency
  3. Oxygen Production and Delivery on Demand

    SBC: Global Research and Development Inc.            Topic: DHA17B005

    This proposal is in response to the Defense Health Agency 2017 Phase I SBIR topic 17B-005.The approach is the use of a membrane oxygen pump using newly developed nano-thickness membranes with all the layers less than 1 micron total.Nanometer thickness membranes enable more oxygen output per surface area at temperatures of 300-600 C than current state-of-the -art 600-800 C membranes that are 50-300 ...

    STTR Phase I 2018 Department of DefenseDefense Health Agency
  4. Griffon Test Suite

    SBC: SOAR TECHNOLOGY, INC.            Topic: DHA17C001

    In this proposal we support the development of a hypoxia test battery by designing and developing a domain general tool suite for processing, synchronizing, and evaluating data from cognitive, behavioral, and physiological measures.The proposed Griffon Tool Suite addresses many of the practical requirements demanded by a flexible test battery. The effort falls into three major thrusts.First, we pr ...

    STTR Phase I 2018 Department of DefenseDefense Health Agency
  5. Validating the MicroKine Assay for Use in Identifying Personalized Precision Therapies for Pediatric Sepsis

    SBC: PreDxion Bio, Inc.            Topic: NICHD

    Project Summary Abstract PreDxion BioLLC is a precision medicine diagnostic company developing an assay platformthe MicroKineassay cartridge and readerthat measures serum proteins in less thanminutes from a single drop of bloodThis fastactionable information allows for the first time individualized precision medicine aimed at reducing pediatric morbidity and mortality in pediatric sepsisthe number ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  6. An Engineered Nanoimmunotherapy for Melanoma

    SBC: ImmunoBlue, LLC            Topic: NCI

    PROJECT SUMMARY Melanoma is one of the most prevalent cancers and is estimated to account for overdeaths inin the United States aloneAlthough highly curable when detected earlytheyear survival rates decline precipitously for patients with regionaland metastaticmelanoma indicating a lack of efficacy of conventional therapiesand a strong need for novel therapies for this patient populationIn respons ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  7. Building an evidentiary case for circulating GHBP as a biomarker for drug-associated stunting of growth

    SBC: ReveraGen BioPharma, Inc.            Topic: NICHD

    There is increasing interest in the use of biomarkers in clinical drug developmentwith much of thest Century Cures Act focused on encouraging this approachIdeallybiomarkers could provide and acute and objective read out of drug mechanism of actionpharmacodynamic biomarkersor prediction of later clinical benefit or harmsurrogate outcome measureHoweververy few biomarkers have been validated for rout ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  8. A universal eye drop adherence monitor to measure and improve adherence to ocular medications

    SBC: Universal Adherence LLC            Topic: N

    Project Summary Abstract Universal Adherence is an emerging medical device company dedicated to improving adherence to ocular medications through innovative technical solutionsOur proposed Devers Drop DeviceDwill accurately track when a patient removes an eye drop bottle capcommunicate usage data wirelessly to a database that researchers can accessand send alerts to patients when a medication is d ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  9. Noninvasive placement and activation of deep-brain stimulating magnetic particles for reduction of drug-seeking behaviors

    SBC: Weinberg Medical Physics, Inc.            Topic: NIDA

    Abstract Deep brain stimulationDBSwith implantable electrodes has been used for reduction of ethanol abuse and drug seeking behaviors in EuropeThe use of such deep brain stimulation procedures has been problematic because of concerns about invasiveness of the procedureApplicant has developed a new noninvasive method of transporting magnetic particles directly to target sites within the brainWe pro ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  10. TFEB Activator for Alzheimer's Disease Therapy

    SBC: BRILLIANT BIOSCIENCES INC.            Topic: NIA

    One in ten of the persons ageare affected by Alzheimer s diseaseADcausing enormous social and economic burden to the United StatesTo date only five medications have been approved by the FDA for the treatment of the symptoms of ADbut none of them slows or stops the disease progressionWith the recent repeated failures of AD drugs on thesecretase inhibitorsthe need for an effective AD drug became eve ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government